Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos inhibidores de la colonización y virulencia de patógenos gastrointestinales

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20170206002
Publicado:
13/03/2017
Caducidad:
13/03/2018
Resumen:
Científicos de un instituto de higiene de una universidad alemana han desarrollado nuevos métodos para preparar oligosacáridos pécticos (POS) y neoglicolípidos (neoGLs), con potencial para inhibir la unión de la toxina Shiga (Stx) a sus receptores genuinos en la superficie celular de un humano o animal. La célula es protegida del daño por la toxina. Los oligosacáridos y neoglicolípidos tienen otras aplicaciones clínicas además del tratamiento de enfermedades intestinales causadas por la bacteria Escherichia coli enterohemorrágica (EHEC) y complicaciones extraintestinales o sistémicas, infecciones del tracto urinario y enfermedad de los edemas en porcinos. El instituto busca licenciatarios.


Details

Tittle:
Novel inhibitors targeting colonization and virulence of gastrointestinal pathogens
Summary:
A technology transfer office in Germany (Bavaria) represents a known German university. Scientists of its institute of hygiene were capable of developing new methods to prepare a number of pectic oligosaccharides (POS) and neoglycolipids (neoGLs) that have the potential to inhibit binding of Shiga Toxin (Stx) to its genuine receptors on the cell surface of a human or animal. Hence, the cell is protected from damage by the Stx. For this technology they are looking for licensees.
Description:
The Technology Transfer Office in Germany, which represents a known German University, is looking for licensees for the newly found method to prepare a number of pectic oligosaccharides and neoglycolipids. They have the potential to prevent diseases caused by toxin-producing pathogens.

Diseases caused by toxin-producing pathogens are a worldwide health threat. Shiga Toxin-producing Escherichia coli and in particular human pathogenic enterohemorrhagic E. coli (EHEC) cause severe intestinal infections such as hemorrhagic colitis and life endangering extraintestinal complications like the hemolytic-uremic syndrome (HUS).  Shiga Toxin represents the major virulence factor of EHEC. So far, no causal treatment of EHEC infections is available. The lack of causal therapy options became evident during large EHEC outbreaks in the past.

Besides treatment of EHEC-caused intestinal diseases and extraintestinal or systemic complications, urinary tract infections and the edema disease of pigs provide further clinical applications of the produced pectic oligosaccharides and neoglycolipids as well.

In addition, there are numerous other implementations to benefit from inhibitory effects of pectic oligosaccharides against toxins released by bacteria into the environment and for adhesive pathogenic bacteria in numerous biological habitats. Such compounds might be useful for example as biological adsorbers of toxins or bacteria in filter systems for drinking water purification, swimming pools or spas, for municipal wastewater treatment and for detoxification of feces in slaughterhouses as well as for air filters of all kinds. Further applications are easily conceivable wherever bacteria-released toxins or adhesive pathogenic bacteria occur.

They now want to enter with their new method into a licensing agreement.
Advantages and Innovations:
- low price of the raw material
- available virtually in unlimited amounts
- non-hazardous for humans and animals
- high ´consumer acceptance`
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT-application filed

Partner sought

Type and Role of Partner Sought:
They are looking for a licensee who is able to prepare the pectic oligosaccharides (POS) and neoglycolipids (neoGLs) with the method provided in this offer and market the products.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001007 Medicina de urgencias
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos
06002010 Toxicología
06001018 Virus, virología / antibióticos / bacteriología